Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

lexipafant

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Background:The management of acute pancreatitis (AP) is still based on speculative and unproven paradigms in many centers… Expand
2005
2005
The aim of the present study was to investigate the potential effect of treatment with a platelet-activating factor (PAF… Expand
Highly Cited
2001
Highly Cited
2001
BACKGROUND Platelet activating factor (PAF) is believed to amplify the activity of key mediators of the systemic inflammatory… Expand
2000
2000
ABSTRACT Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of… Expand
Highly Cited
1999
Highly Cited
1999
Objective: To assess the safety and tolerability of lexipafant in HIV-associated cognitive impairment. Background: Cognitive… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
1999
Highly Cited
1999
Endothelial barrier dysfunction is a critical link in the development of tissue injury and organ dysfunction, via upregulation… Expand
1999
1999
Bacterial translocation (BT) from the gastrointestinal tract to mesenteric lymph nodes (MLNs) and other extra intestinal organs… Expand
Highly Cited
1997
Highly Cited
1997
Background Many patients with severe acute pancreatitis develop organ system failure during the first few days of illness, and… Expand
1996
1996
Acute pancreatitis is associated with the development of pulmonary dysfunction in a number of patients. The aim of this study was… Expand
Highly Cited
1995
Highly Cited
1995
The aims of the study were to determine whether the platelet‐activating factor antagonist Lexipafant could alter the clinical… Expand